


COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
 (Currently amended claims showing deletions by ~~striketrough~~ and additions by underlining)

In the Claims

1. (Canceled)

2. (Currently amended) A pharmaceutical composition ~~according to claim 1,~~
comprising a farnesyl transferase inhibitor, or a pharmaceutically acceptable salt thereof,
and an anthracycline, or a pharmaceutically acceptable salt thereof,

wherein said farnesyl transferase inhibitor is according to formula I:



(I)

wherein

n1 is 0 or 1;


X is, independently for each occurrence, (CHR¹¹)_{n3}(CH₂)_{n4}Z(CH₂)_{n5};

Z is O, N(R¹²), S, or a bond;

n3 is, independently for each occurrence, 0 or 1;

n4 and n5 each is, independently for each occurrence, 0, 1, 2, or 3;

Y is, independently for each occurrence, CO, CH₂, CS, or a bond;



R², R¹¹, and R¹² each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl and aryl, wherein said optionally substituted moiety is optionally substituted with one or more of R⁸ or R³⁰;

R³ is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more R³⁰;

R⁴ and R⁵ each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, aryl, and heterocyclyl, wherein said optionally substituted moiety is optionally substituted with one or more R³⁰, wherein each said substituent is independently selected, or R⁴ and R⁵ can be taken together with the carbons to which they are attached to form aryl;

R⁶ is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each

independently selected from the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, -N(R⁸R⁹), -COOH, -CON(R⁸R⁹), and halo,

where R⁸ and R⁹ each is, independently for each occurrence, H, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, aryl, or aryl(C₁₋₆)alkyl;


R⁷ is, independently for each occurrence, H, =O, =S, or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, -N(R⁸R⁹), -COOH, -CON(R⁸R⁹), and halo;

R¹⁰ is C;

or when n₁ = 0, R⁶ and R⁷ can be taken together with the carbon atoms to which they are attached to form aryl or cyclohexyl;

R²¹ is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl and aryl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of R⁸ and R³⁰;

R²² is H, (C₁₋₆)alkylthio, (C₃₋₆)cycloalkylthio, R⁸-CO-, or a substituent according to the



formula

R²⁴ and R²⁵ each is, independently for each occurrence, H, (C₁₋₆)alkyl, or aryl(C₁₋₆)alkyl;

R³⁰ is, independently for each occurrence, (C₁₋₆)alkyl, -O-R⁸, -S(O)_{n6}R⁸, -

S(O)_{n7}N(R⁸R⁹),


$-N(R^8R^9)$, $-CN$, $-NO_2$, $-CO_2R^8$, $-CON(R^8R^9)$, $-NCO-R^8$, or halogen;

n_6 and n_7 each is, independently for each occurrence, 0, 1, or 2;


wherein said heterocyclcyl is azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothieryl, benzoxazolyl, chromanyl, cinnoliny, dihydrobenzofuryl, dihydrobenzothieryl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indoliny, indolyl, isochromanyl, isoindoliny, isoquinoliny, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholiny, naphthyridiny, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, quinoxaliny, tetrahydrofuryl, tetrahydroisoquinoliny, tetrahydro-quinoliny, thiamorpholiny, thiamorpholiny sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothieryl, or thienyl; and wherein said aryl is phenyl or naphthyl;

provided that:

when $n_1 = 1$, R^{10} is C and R^6 is H, then R^{10} and R^7 can be taken together to form




when $n_1 = 1$, R^{10} is C, and R^7 is $=O$, $-H$, or $=S$, then R^{10} and R^6 can be taken together to



wherein X^1 , X^2 , and X^3 each is, independently, H, halogen, $-NO_2$, $-NCO-R^8$, $-CO_2R^8$, $-CN$, or $-CON(R^8R^9)$; and

when R^1 is $N(R^{24}R^{25})$, then n_3 is 1, n_4 and n_5 each is 0, Z is a bond, and R^3 and R^{11} can be




taken together to form

wherein n_2 is 1-6, and X^4 and X^5 each is, independently, H, (C_{1-6}) alkyl, or aryl, or X^4 and X^5 can be taken together to form (C_{3-6}) cycloalkyl;

or a pharmaceutically acceptable salt thereof.

3. (Original) A pharmaceutical composition according to claim 2, wherein:




and

X is $CH(R^{11})_{n_3}(CH_2)_{n_4}$ or Z , wherein when X is Z , Z is O, S, or $N(R^{12})$;

or a pharmaceutically acceptable salt thereof.

4. (Original) A pharmaceutical composition according to claim 3, wherein:




X is $CH(R^{11})_{n_3}(CH_2)_{n_4}$; and

n_1 is 0;

or a pharmaceutically acceptable salt thereof.

5. (Original) A pharmaceutical composition according to claim 3, wherein:



n₃, n₄, and n₅ each is 0;


Z is a bond;

Y is, independently for each occurrence, CO or CS; and

n₁ is 0;


or a pharmaceutically acceptable salt thereof.

6. (Original) A pharmaceutical composition according to claim 3, wherein:



R⁶ is H;

n₁ is 1;



n₃ is 1 and R¹¹ is H;

Z is O or a bond;

n₅ is 0; and

Y is CO, CH₂, or a bond;

or a pharmaceutically acceptable salt thereof.

7. (Original) A pharmaceutical composition according to claim 3, wherein:

R¹ is N(R²⁴R²⁵);

n1 is 0;


n3 is 1;

n4 is 0;

n5 is 0;


Y is CO or CS;

Z is a bond; and




R³ and R¹¹ are taken together to form
or a pharmaceutically acceptable salt thereof.

8. (Original) A pharmaceutical composition according to claim 3, wherein said farnesyl transferase inhibitor is a compound of formula I, wherein:



R⁷ is H or =O;

n1 is 1;



R⁶ and R¹⁰ are taken together to form

n3 is 1 and R¹¹ is H;

n5 is 0;

Y is CO or CH₂; and

Z is O or a bond;

or a pharmaceutically acceptable salt thereof.

9. (Original) A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:

8-butyl-7-(3-(imidazol-5-yl)-1-oxopropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-2-(2-hydroxyphenyl)-7-(imidazol-4-yl-propyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-7-(4-imidazolylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(imidazol-4-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(1-oxo-2-(1-(phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((1H-imidazol-4-yl)methyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((4-imidazolyl)carbonyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(1-(4-cyanophenylmethyl)-imidazol-5-yl)methyl-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

5-butyl-7-(2-(1H-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-(phenylmethoxy)-phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or

2-(2-butoxyphenyl)-7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

or a pharmaceutically acceptable salt thereof.

10. (Original) A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:

1,2-dihydro-1-((1H-imidazol-4-yl)methyl)-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-Chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-Bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or
or a pharmaceutically acceptable salt thereof.

11. (Previously presented) A pharmaceutical composition according to claim 10, wherein said farnesyl transferase inhibitor is:

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-Chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-Bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine.

12. (Previously presented) A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:

7-(2-amino-1-oxo-3-thiopropyl)-8-(mercaptoethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine disulfide;
or a pharmaceutically acceptable salt thereof.

13. (Previously presented) A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:

5-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6-dihydro-2-phenyl-1H-imidazo[1,2-a][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.

14. (Previously presented) A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:




1,2-dihydro-1-(2-(imidazol-1-yl)-1-oxoethyl)-4-(2-methoxyphenyl)
imidazo[1,2a][1,4]benzodiazepine;







1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-3-yl)-1-oxoethyl)
imidazo[1,2a][1,4]benzodiazepine; or







1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-4-yl)-1-oxoethyl)
imidazo[1,2a][1,4]benzodiazepine;







or a pharmaceutically acceptable salt thereof.







15. (Original) A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:


























or a pharmaceutically acceptable salt thereof.

16. (Original) A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:








or a pharmaceutically acceptable salt thereof.

17. (Original) A pharmaceutical composition according to claim 16, wherein said farnesyl transferase inhibitor is:



or a pharmaceutically acceptable salt thereof.

18. (Currently amended) A pharmaceutical composition according to claim 17,

wherein said ~~anthracyclin~~ anthracycline is doxorubicin, daunorubicin, epirubicin, idarubicin, or amrubicin, or a pharmaceutically acceptable salt thereof.

19. (Currently amended) A pharmaceutical composition according to claim 17, wherein said ~~anthracyclin~~ anthracycline is doxorubicin, or a pharmaceutically acceptable salt thereof.

20. (Currently amended) A pharmaceutical composition according to claim ~~[[1]]~~ 2, wherein said ~~anthracyclin~~ anthracycline is doxorubicin, daunorubicin, epirubicin, idarubicin, or amrubicin, ~~or a prodrug thereof~~, or a pharmaceutically acceptable salt of said ~~anthracyclin~~ anthracycline ~~or of said anthracyclin prodrug~~.

21. (Currently amended) A pharmaceutical composition according to claim 20, wherein said ~~anthracyclin~~ anthracycline is doxorubicin, or a pharmaceutically acceptable salt thereof.

22. (Previously presented) A method of decreasing the rate of proliferation of nasopharyngeal carcinoma cells, said method comprising contacting said nasopharyngeal cells with a pharmaceutical composition according to any one of claims 18 - 21.

23 – 25. (Canceled)

26. (Previously presented) A method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient a pharmaceutical composition according to any one of claims 18 - 21.

27 – 29. (Canceled)

30. (Currently amended) A method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient an effective amount of one or more farnesyl transferase ~~inhibiting compound~~ inhibitor according to claim 2 in combination with an effective amount of one or more anthracycline ~~compound~~, wherein said effective amount of said farnesyl transferase ~~inhibiting compound~~ inhibitor or ~~compounds~~ inhibitors and of said anthracycline ~~compound or compounds~~ or anthracyclines are effective in combination to treat said nasopharyngeal carcinoma.

31. (Original) A method according to claim 30 wherein said patient is a mammal.

32. (Original) A method according to claim 31 wherein said patient is a human being.

33. (Currently amended) A method according to claim 32 wherein said farnesyl transferase ~~inhibiting compound~~ inhibitor and said anthracycline ~~compound~~ are administered substantially simultaneously.

34. (Original) A pharmaceutical kit comprising a composition according to claim 18 and instructions for use of said composition for the treatment of nasopharyngeal carcinoma.

35 – 37. (Canceled)

38. (Currently amended) A kit comprising: a) a first unit dosage form comprising a farnesyl transferase inhibitor according to claim 2, ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof ~~of said farnesyl transferase inhibitor or of said farnesyl transferase inhibitor prodrug~~ and a pharmaceutically acceptable carrier, vehicle or diluent; b) a second unit dosage form comprising an anthracycline, ~~a prodrug thereof~~

or a pharmaceutically acceptable salt thereof ~~of said anthracycline or of said anthracycline prodrug~~ and a pharmaceutically acceptable carrier, vehicle or diluent; and
c) a container.

39 - 40. (Canceled)